not long now

with AGM coming up at end of next month approx, I'm expecting company to deliver on previous commitments ie , developing relationship with pharma and/or news on the Becca situation.I'm no expert on POH but they have a pharma on board / early stage reationship with cosmetic company but as far as I can tell no sales revenue , but a market cap of $220m!! Clearly they are further down the road however all of their trandermal delivery drug canditates are modified by the phosphagen addative and therefore will require reapplication for approval of a basically new drug ie several years to cashflow. With OBJ at 1/10 the mkt cap
and no change to the drugs they are delivering, if they can snare the support of one of the major pharmas (which may be close at hand)that should place their mkt cap somewhere between here and POH at $220m imo....heres's hoping